IP Library › Granted Patent US 9,200,273
Granted Patent B2
US 9,200,273 · App. 13/628,393 · Granted Dec 1, 2015

Fibronectin type III repeat based protein scaffolds with alternative binding surfaces

Inventors: Michael Diem (Radnor, PA); Steven Jacobs (Radnor, PA)
Assignee: Janssen Biotech, Inc.
C12N15/1044C40B40/08C40B50/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,200,273
App. No.
13/628,393
Granted
Dec 1, 2015
Kind
B2
Abstract

Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) repeat with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Claims (10)

1. A method of making a library of fibronectin module of type III (FN3) domains having a diversified C-CD-F-FG alternative surface formed by a C beta-strand, a CD loop, an F beta-strand, and an FG loop, comprising

a. providing a reference FN3 domain polypeptide having the amino acid sequence at least 80% identical to that of SEQ ID NO: 27;

b. introducing diversity into the reference FN3 domain polypeptide by mutating at least one C beta-strand residue and at least one F beta-strand residue to form the FN3 domain library having the diversified C-CD-F-FG alternative surface, wherein the at least one residue in the C beta-strand is mutated with the proviso that S30 is not mutated (residue numbering according to SEQ ID NO: 27), wherein the at least one residue in the F beta-strand is mutated with the proviso that E66 is not mutated (residue numbering according to SEQ ID NO: 27), wherein each of the C beta-strand residues L32, Q34 and Q36 are mutated (residue numbering according to SEQ ID NO: 27) or each of the F-beta strand residues T68, S70 and Y72 are mutated (residue numbering according to SEQ ID NO: 27).

2. The method of claim 1 , wherein 1, 2, 3 or 4 residues in the CD loop residues are mutated with the proviso that G42 and E43 are not mutated (residues numbering according to SEQ ID NO: 27).

3. The method of claim 2 , wherein the residues S38, E39, K40 and V41 in the CD loop are mutated.

4. The method of claim 3 , wherein 1, 2, 3 or 4 residues in the FG loop are mutated with the proviso that the residues K75, G76, G77 and S80 are not mutated (residue numbering according to SEQ ID NO: 27).

5. The method of claim 4 , wherein the residues H78, R79 and N81 in the FG loop are mutated (residue numbering according to SEQ ID NO: 27).

6. The method of claim 5 , wherein the reference FN3 domain comprises an amino acid sequence of SEQ ID NO: 27, optionally comprising at least one substitution at amino acid positions 11, 14, 17, 37, 46, 73, or 86.

7. A library produced by the method of claim 1 .

8. The library of claim 7 , wherein the library comprises an amino acid sequence of SEQ ID NO: 28.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2019
From: DIEM, MICHAEL; JACOBS, STEVEN
To: JANSSEN BIOTECH, INC.
Reel/Frame 049735/0686 →
Continuity (2)
Provisional Application 61539670 · Sep 27, 2011
Related Publication 20130079243A1 · Mar 28, 2013